First-lineNovoRapid, Humulin I
Insulin (Aspart / Isophane)
Short- and intermediate-acting insulins
Mainstay for T1DM, severe GDM, and DKA in pregnancy.
SubcutaneousIV (DKA / labour)
First-line for
- Type 1 DM in pregnancy
- GDM not controlled on metformin
- DKA in pregnancy
Mechanism
Activates insulin receptor → glucose uptake (muscle/fat), ↓ hepatic glucose output, ↓ lipolysis & ketogenesis.
“5.3 / 7.8” pregnancy targets
- Fasting <5.3 mmol/L
- 1 h post-meal <7.8 mmol/L
- 2 h post-meal <6.4 mmol/L
- Avoid <4 mmol/L (hypoglycaemia)
Dosing
- Basal-bolus
- Individualised; needs ↑ ~50% by T3
- Sliding scale (labour)
- Variable rate IV insulin + 10% dextrose
- DKA
- 0.1 units/kg/h IV after fluid resuscitation
Contraindications
- AbsoluteHypoglycaemia
- CautionDrop dose 50% immediately postpartum to pre-pregnancy levels
Side effects
- Hypoglycaemia
- Weight gain
- Lipohypertrophy at injection sites
Fetal & maternal notes
- • Does not cross placenta.
- • Tight glycaemic control reduces macrosomia, neonatal hypoglycaemia, stillbirth.
Key interactions
Betamethasone (lung maturation)
CautionHyperglycaemia 24–72 h — ↑ insulin requirement
Beta-blockers
CautionMask hypoglycaemia awareness
Clinical pearls
- 💡 Always co-prescribe glucagon for severe hypo.
- 💡 Pre-conception folic acid 5 mg + tight HbA1c <48 mmol/mol.
Content last reviewed: REPLACE_ME (e.g. 2026-07)
Spotted something out of date? See our disclaimer or use Report an Error above.